We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-0.85%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$471M
AUM Growth
-$63.9M
Cap. Flow
-$5.68M
Cap. Flow %
-1.2%
Top 10 Hldgs %
58.75%
Holding
54
New
6
Increased
11
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$25.5M
2
DNA icon
Ginkgo Bioworks
DNA
+$11M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$7.95M
4
MRUS
Merus
MRUS
+$6.15M
5
HYPR icon
Hyperfine
HYPR
+$6.04M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$7.76M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$7.17M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.98M
4
CLDX icon
Celldex Therapeutics
CLDX
+$6.14M
5
SMLR
Semler Scientific
SMLR
+$6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TELA icon
26
TELA Bio
TELA
$29.2M
$5.76M 1.22%
449,867
+6,668
+2% +$84.5K
HYPR icon
27
Hyperfine
HYPR
$89.7M
$5.52M 1.17%
+763,075
New +$6.04M
BBIO icon
28
BridgeBio Pharma
BBIO
$15.4B
$5.47M 1.16%
328,100
-183,400
-36% -$7.76M
NGNE icon
29
Neurogene
NGNE
$758M
$5.05M 1.07%
52,365
– –
FDMT icon
30
4D Molecular Therapeutics
FDMT
$824M
$5.02M 1.07%
+229,000
New +$5.61M
VSTM icon
31
Verastem
VSTM
$668M
$4.77M 1.01%
193,750
– –
SRRA
32
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.6M 0.76%
165,778
– –
LITS
33
Lite Strategy Inc
LITS
$34M
$3.51M 0.74%
65,750
-12,500
-16% -$697K
NCNA
34
NuCana
NCNA
$6.12M
$2.83M 0.6%
238
+142
+148% +$1.78M
AVTX icon
35
Avalo Therapeutics
AVTX
$1.08B
$2.48M 0.53%
507
– –
SYBX
36
DELISTED
Synlogic
SYBX
$2.06M 0.44%
+56,667
New +$2.2M
AVEO
37
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.24M 0.26%
263,400
-192,200
-42% -$1.19M
LQDA icon
38
Liquidia Corp
LQDA
$6.26B
$82K 0.02%
+16,800
New +$67K
BLRX
39
BioLineRX
BLRX
$12.1M
$34K 0.01%
417
– –
AKBA icon
40
Akebia Therapeutics
AKBA
$260M
– –
-311,300
Closed -$897K
DTIL icon
41
Precision BioSciences
DTIL
$232M
– –
-5,463
Closed -$1.89M
FOLD
42
DELISTED
Amicus Therapeutics
FOLD
– –
-320,800
Closed -$3.06M
CYPH
43
Cypherpunk Technologies Inc
CYPH
$204M
– –
-47,600
Closed -$1.91M
OPTN
44
DELISTED
OptiNose
OPTN
– –
-103,900
Closed -$4.68M
RNAC icon
45
Cartesian Therapeutics
RNAC
$302M
– –
-3,533
Closed -$441K
WHWK
46
Whitehawk Therapeutics
WHWK
$278M
– –
-45,020
Closed -$1.32M
VIRX
47
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-258,556
Closed -$2.07M
DCPH
48
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-205,381
Closed -$6.98M
AFIB
49
DELISTED
Acutus Medical Inc
AFIB
– –
-590,000
Closed -$5.22M
CBAY
50
DELISTED
Cymabay Therapeutics
CBAY
– –
-115,015
Closed -$420K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2021 Portfolio in Review

As of Q4 2021, Opaleye Management held 54 positions worth $471M, down 12% from $535M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management's Q4 2021 filing shows 6 new, 11 increased, 10 reduced and 15 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 330,000 shares worth $8.7M. The largest sale was BridgeBio Pharma, an estimated $7.76M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Opaleye Management's largest Q4 2021 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 330,000 shares worth $8.7M.
  • Opaleye Management added most to Crinetics Pharmaceuticals in Q4 2021, an estimated $7.95M increase.
  • Opaleye Management's biggest Q4 2021 reduction was BridgeBio Pharma, cutting an estimated $7.76M.
  • Opaleye Management fully exited Adamas Pharmaceuticals in Q4 2021, selling an estimated $7.17M.
  • Opaleye Management's ten largest holdings make up 59% of its $471M portfolio in Q4 2021.
  • Opaleye Management opened 6 new positions and closed 15 in Q4 2021.
  • Opaleye Management's portfolio value fell 12% quarter-over-quarter to $471M.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.